Infliximab :: pharmacology, uses and limitations /
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Science Publishers, Incorporated,
[2012]
|
| Schriftenreihe: | Immunology and immune system disorders.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 1 online resource. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781619423459 1619423456 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1162002557 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 120802s2012 nyu ob 001 0 eng | ||
| 010 | |a 2020677201 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d VLY |d OCLCO |d AZK |d YDXCP |d N$T |d E7B |d OCLCF |d NLGGC |d EBLCP |d LOA |d MERUC |d AGLDB |d ICA |d MOR |d PIFAG |d ZCU |d U3W |d D6H |d STF |d WRM |d VTS |d NRAMU |d ICG |d VT2 |d WYU |d DKC |d AU@ |d M8D |d K6U |d UKCRE |d AJS |d OCLCO |d OCLCQ |d OCLCO |d OCLCL |d TMA |d OCLCQ | ||
| 019 | |a 828140625 |a 923654270 |a 961573436 |a 962684398 |a 966182436 |a 988436558 |a 992028910 |a 1037927216 |a 1038665338 |a 1045509625 |a 1055383791 |a 1066451555 |a 1081210814 |a 1153513512 | ||
| 020 | |a 9781619423459 |q (ebook) | ||
| 020 | |a 1619423456 | ||
| 020 | |z 9781619423435 | ||
| 020 | |z 161942343X |q (hbk.) | ||
| 035 | |a (OCoLC)1162002557 |z (OCoLC)828140625 |z (OCoLC)923654270 |z (OCoLC)961573436 |z (OCoLC)962684398 |z (OCoLC)966182436 |z (OCoLC)988436558 |z (OCoLC)992028910 |z (OCoLC)1037927216 |z (OCoLC)1038665338 |z (OCoLC)1045509625 |z (OCoLC)1055383791 |z (OCoLC)1066451555 |z (OCoLC)1081210814 |z (OCoLC)1153513512 | ||
| 050 | 0 | 0 | |a RM405.5 |
| 060 | 4 | |a WD 305 | |
| 072 | 7 | |a MED |x 044000 |2 bisacsh | |
| 082 | 7 | |a 615.7/94 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Infliximab : |b pharmacology, uses and limitations / |c Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors. |
| 264 | 1 | |a New York : |b Nova Science Publishers, Incorporated, |c [2012] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 380 | |a Bibliography | ||
| 490 | 1 | |a Immunology and immune system disorders | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Description based on print version record. | ||
| 505 | 0 | |a ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" | |
| 505 | 8 | |a ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�s Disease ""; ""Fistulizing Crohn�s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" | |
| 505 | 8 | |a ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" | |
| 505 | 8 | |a ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" | |
| 546 | |a English. | ||
| 650 | 0 | |a Infliximab. |0 http://id.loc.gov/authorities/subjects/sh2002010978 | |
| 650 | 0 | |a Infliximab |x Therapeutic use. | |
| 650 | 0 | |a Anti-inflammatory agents. |0 http://id.loc.gov/authorities/subjects/sh85005615 | |
| 650 | 2 | |a Autoimmune Diseases |x drug therapy | |
| 650 | 2 | |a Anti-Inflammatory Agents |0 https://id.nlm.nih.gov/mesh/D000893 | |
| 650 | 6 | |a Infliximab. | |
| 650 | 6 | |a Infliximab |x Emploi en thérapeutique. | |
| 650 | 6 | |a Antiinflammatoires. | |
| 650 | 7 | |a MEDICAL |x Immunology. |2 bisacsh | |
| 650 | 7 | |a Autoimmune diseases |x Chemotherapy |2 fast | |
| 650 | 7 | |a Infliximab |2 fast | |
| 700 | 1 | |a Medrano Acevedo, Antonio D. | |
| 700 | 1 | |a Fajardo Gaitan, Montserrat. | |
| 758 | |i has work: |a Infliximab (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYhFKP997HfCrkffDB4BxC |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Infliximab |d [Hauppauge] New York : Nova Science Publishers, Inc., [2012] |z 9781619423435 |w (DLC) 2012418415 |
| 830 | 0 | |a Immunology and immune system disorders. |0 http://id.loc.gov/authorities/names/n2010183470 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3017947 | ||
| 938 | |a ebrary |b EBRY |n ebr10654918 | ||
| 938 | |a EBSCOhost |b EBSC |n 540914 | ||
| 938 | |a YBP Library Services |b YANK |n 7252252 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1162002557 |
|---|---|
| _version_ | 1816882521155043328 |
| adam_text | |
| any_adam_object | |
| author2 | Medrano Acevedo, Antonio D. Fajardo Gaitan, Montserrat |
| author2_role | |
| author2_variant | a a d m aad aadm g m f gm gmf |
| author_facet | Medrano Acevedo, Antonio D. Fajardo Gaitan, Montserrat |
| author_sort | Medrano Acevedo, Antonio D. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM405 |
| callnumber-raw | RM405.5 |
| callnumber-search | RM405.5 |
| callnumber-sort | RM 3405.5 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�s Disease ""; ""Fistulizing Crohn�s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" |
| ctrlnum | (OCoLC)1162002557 |
| dewey-full | 615.7/94 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7/94 |
| dewey-search | 615.7/94 |
| dewey-sort | 3615.7 294 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05682cam a2200709 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1162002557</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">120802s2012 nyu ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2020677201</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AZK</subfield><subfield code="d">YDXCP</subfield><subfield code="d">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLGGC</subfield><subfield code="d">EBLCP</subfield><subfield code="d">LOA</subfield><subfield code="d">MERUC</subfield><subfield code="d">AGLDB</subfield><subfield code="d">ICA</subfield><subfield code="d">MOR</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">U3W</subfield><subfield code="d">D6H</subfield><subfield code="d">STF</subfield><subfield code="d">WRM</subfield><subfield code="d">VTS</subfield><subfield code="d">NRAMU</subfield><subfield code="d">ICG</subfield><subfield code="d">VT2</subfield><subfield code="d">WYU</subfield><subfield code="d">DKC</subfield><subfield code="d">AU@</subfield><subfield code="d">M8D</subfield><subfield code="d">K6U</subfield><subfield code="d">UKCRE</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">TMA</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">828140625</subfield><subfield code="a">923654270</subfield><subfield code="a">961573436</subfield><subfield code="a">962684398</subfield><subfield code="a">966182436</subfield><subfield code="a">988436558</subfield><subfield code="a">992028910</subfield><subfield code="a">1037927216</subfield><subfield code="a">1038665338</subfield><subfield code="a">1045509625</subfield><subfield code="a">1055383791</subfield><subfield code="a">1066451555</subfield><subfield code="a">1081210814</subfield><subfield code="a">1153513512</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781619423459</subfield><subfield code="q">(ebook)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1619423456</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781619423435</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">161942343X</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1162002557</subfield><subfield code="z">(OCoLC)828140625</subfield><subfield code="z">(OCoLC)923654270</subfield><subfield code="z">(OCoLC)961573436</subfield><subfield code="z">(OCoLC)962684398</subfield><subfield code="z">(OCoLC)966182436</subfield><subfield code="z">(OCoLC)988436558</subfield><subfield code="z">(OCoLC)992028910</subfield><subfield code="z">(OCoLC)1037927216</subfield><subfield code="z">(OCoLC)1038665338</subfield><subfield code="z">(OCoLC)1045509625</subfield><subfield code="z">(OCoLC)1055383791</subfield><subfield code="z">(OCoLC)1066451555</subfield><subfield code="z">(OCoLC)1081210814</subfield><subfield code="z">(OCoLC)1153513512</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RM405.5</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WD 305</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">044000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7/94</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Infliximab :</subfield><subfield code="b">pharmacology, uses and limitations /</subfield><subfield code="c">Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Science Publishers, Incorporated,</subfield><subfield code="c">[2012]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="380" ind1=" " ind2=" "><subfield code="a">Bibliography</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Immunology and immune system disorders</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Infliximab.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh2002010978</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Infliximab</subfield><subfield code="x">Therapeutic use.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Anti-inflammatory agents.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85005615</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Autoimmune Diseases</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Anti-Inflammatory Agents</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000893</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infliximab.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Infliximab</subfield><subfield code="x">Emploi en thérapeutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Antiinflammatoires.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Immunology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autoimmune diseases</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Infliximab</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Medrano Acevedo, Antonio D.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fajardo Gaitan, Montserrat.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Infliximab (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCYhFKP997HfCrkffDB4BxC</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Infliximab</subfield><subfield code="d">[Hauppauge] New York : Nova Science Publishers, Inc., [2012]</subfield><subfield code="z">9781619423435</subfield><subfield code="w">(DLC) 2012418415</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Immunology and immune system disorders.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2010183470</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL3017947</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10654918</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">540914</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">7252252</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-on1162002557 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:29:56Z |
| institution | BVB |
| isbn | 9781619423459 1619423456 |
| language | English |
| lccn | 2020677201 |
| oclc_num | 1162002557 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Nova Science Publishers, Incorporated, |
| record_format | marc |
| series | Immunology and immune system disorders. |
| series2 | Immunology and immune system disorders |
| spelling | Infliximab : pharmacology, uses and limitations / Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors. New York : Nova Science Publishers, Incorporated, [2012] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda Bibliography Immunology and immune system disorders Includes bibliographical references and index. Description based on print version record. ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" English. Infliximab. http://id.loc.gov/authorities/subjects/sh2002010978 Infliximab Therapeutic use. Anti-inflammatory agents. http://id.loc.gov/authorities/subjects/sh85005615 Autoimmune Diseases drug therapy Anti-Inflammatory Agents https://id.nlm.nih.gov/mesh/D000893 Infliximab. Infliximab Emploi en thérapeutique. Antiinflammatoires. MEDICAL Immunology. bisacsh Autoimmune diseases Chemotherapy fast Infliximab fast Medrano Acevedo, Antonio D. Fajardo Gaitan, Montserrat. has work: Infliximab (Text) https://id.oclc.org/worldcat/entity/E39PCYhFKP997HfCrkffDB4BxC https://id.oclc.org/worldcat/ontology/hasWork Print version: Infliximab [Hauppauge] New York : Nova Science Publishers, Inc., [2012] 9781619423435 (DLC) 2012418415 Immunology and immune system disorders. http://id.loc.gov/authorities/names/n2010183470 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914 Volltext |
| spellingShingle | Infliximab : pharmacology, uses and limitations / Immunology and immune system disorders. ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohnâ€?s Disease ""; ""Fistulizing Crohnâ€?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" ""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" Infliximab. http://id.loc.gov/authorities/subjects/sh2002010978 Infliximab Therapeutic use. Anti-inflammatory agents. http://id.loc.gov/authorities/subjects/sh85005615 Autoimmune Diseases drug therapy Anti-Inflammatory Agents https://id.nlm.nih.gov/mesh/D000893 Infliximab. Infliximab Emploi en thérapeutique. Antiinflammatoires. MEDICAL Immunology. bisacsh Autoimmune diseases Chemotherapy fast Infliximab fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh2002010978 http://id.loc.gov/authorities/subjects/sh85005615 https://id.nlm.nih.gov/mesh/D000893 |
| title | Infliximab : pharmacology, uses and limitations / |
| title_auth | Infliximab : pharmacology, uses and limitations / |
| title_exact_search | Infliximab : pharmacology, uses and limitations / |
| title_full | Infliximab : pharmacology, uses and limitations / Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors. |
| title_fullStr | Infliximab : pharmacology, uses and limitations / Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors. |
| title_full_unstemmed | Infliximab : pharmacology, uses and limitations / Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors. |
| title_short | Infliximab : |
| title_sort | infliximab pharmacology uses and limitations |
| title_sub | pharmacology, uses and limitations / |
| topic | Infliximab. http://id.loc.gov/authorities/subjects/sh2002010978 Infliximab Therapeutic use. Anti-inflammatory agents. http://id.loc.gov/authorities/subjects/sh85005615 Autoimmune Diseases drug therapy Anti-Inflammatory Agents https://id.nlm.nih.gov/mesh/D000893 Infliximab. Infliximab Emploi en thérapeutique. Antiinflammatoires. MEDICAL Immunology. bisacsh Autoimmune diseases Chemotherapy fast Infliximab fast |
| topic_facet | Infliximab. Infliximab Therapeutic use. Anti-inflammatory agents. Autoimmune Diseases drug therapy Anti-Inflammatory Agents Infliximab Emploi en thérapeutique. Antiinflammatoires. MEDICAL Immunology. Autoimmune diseases Chemotherapy Infliximab |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914 |
| work_keys_str_mv | AT medranoacevedoantoniod infliximabpharmacologyusesandlimitations AT fajardogaitanmontserrat infliximabpharmacologyusesandlimitations |